Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
Annexon (Nasdaq: ANNX), a biopharmaceutical company focused on classical complement-mediated neuroinflammatory diseases, has granted stock options to a new non-executive employee. The inducement grant was approved on August 11, 2025, under the company's 2022 Employment Inducement Award Plan and Nasdaq Listing Rule 5635(c)(4).
The grant consists of options to purchase 60,000 shares of Annexon common stock at an exercise price of $2.44 per share. The options have a ten-year term and vest over four years, with 25% vesting after one year and the remainder vesting monthly over the following three years.
Annexon (Nasdaq: ANNX), società biofarmaceutica specializzata in malattie neuroinfiammatorie mediate dal complemento classico, ha assegnato opzioni su azioni a un nuovo dipendente non esecutivo. L'assegnazione come incentivo è stata approvata l'11 agosto 2025 ai sensi del Piano di Assegnazione Incentivi per l'Occupazione 2022 dell'azienda e della Regola 5635(c)(4) di Nasdaq.
Il pacchetto prevede opzioni per l'acquisto di 60.000 azioni ordinarie di Annexon a un prezzo di esercizio di $2,44 per azione. Le opzioni hanno una durata di dieci anni e maturano in quattro anni: il 25% matura dopo un anno, mentre il restante 75% matura mensilmente nei tre anni successivi.
Annexon (Nasdaq: ANNX), una compañía biofarmacéutica centrada en enfermedades neuroinflamatorias mediadas por el complemento clásico, ha concedido opciones sobre acciones a un nuevo empleado no ejecutivo. La concesión como incentivo fue aprobada el 11 de agosto de 2025, según el Plan de Premios por Inducción al Empleo 2022 de la empresa y la Norma 5635(c)(4) de Nasdaq.
La adjudicación comprende opciones para comprar 60.000 acciones ordinarias de Annexon a un precio de ejercicio de $2,44 por acción. Las opciones tienen un plazo de diez años y se consolidan a lo largo de cuatro años: el 25% se consolida tras un año y el resto se consolida mensualmente durante los tres años siguientes.
Annexon (Nasdaq: ANNX), 고전적 보체 매개 신경염증 질환에 주력하는 바이오제약 회사가 새로운 비임원 직원에게 주식매수선택권을 부여했습니다. 이 유인 보상 부여는 회사의 2022 고용 유인 보상 계획과 Nasdaq 상장 규칙 5635(c)(4)에 따라 2025년 8월 11일 승인되었습니다.
부여 내용은 Annexon 보통주 60,000주를 주당 $2.44의 행사 가격으로 매수할 수 있는 옵션입니다. 옵션의 유효기간은 10년이며, 권리는 4년에 걸쳐 취득됩니다. 25%는 1년 후 취득되며 나머지는 이어지는 3년 동안 매월 나누어 취득됩니다.
Annexon (Nasdaq: ANNX), une société biopharmaceutique spécialisée dans les maladies neuroinflammatoires médiées par le complément classique, a accordé des options d'achat d'actions à un nouveau salarié non exécutif. L'attribution en tant qu'incitation a été approuvée le 11 août 2025, conformément au Plan d'attribution d'incitation à l'emploi 2022 de la société et à la règle 5635(c)(4) de Nasdaq.
La délivrance comprend des options d'achat de 60 000 actions ordinaires d'Annexon à un prix d'exercice de 2,44 $ par action. Les options ont une durée de dix ans et se gagnent sur quatre ans : 25 % se gagnent après un an, le reste se gagne mensuellement au cours des trois années suivantes.
Annexon (Nasdaq: ANNX), ein biopharmazeutisches Unternehmen, das sich auf klassische komplementvermittelte neuroinflammatorische Erkrankungen konzentriert, hat einem neuen nicht geschäftsführenden Mitarbeiter Aktienoptionen gewährt. Die Anreizzuteilung wurde am 11. August 2025 genehmigt, gemäß dem Employment Inducement Award Plan 2022 des Unternehmens und der Nasdaq-Listing-Regel 5635(c)(4).
Die Zuteilung umfasst Optionen zum Kauf von 60.000 Aktien der Annexon-Stammaktien zu einem Ausübungspreis von $2,44 pro Aktie. Die Optionen haben eine Laufzeit von zehn Jahren und vesten über vier Jahre: 25 % vesten nach einem Jahr, die restlichen 75 % vesten monatlich über die folgenden drei Jahre.
- None.
- None.
BRISBANE, Calif., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that it has granted inducement to a new non-executive employee under the terms of the 2022 Employment Inducement Award Plan. The equity award was approved on August 11, 2025, in accordance with Nasdaq Listing Rule 5635(c)(4).
The new non-executive employee received an option to purchase 60,000 shares of Annexon common stock. The option carries a ten-year term and an exercise price per share equal to
About Annexon
Annexon Biosciences (Nasdaq: ANNX) is developing therapeutics that stop classical complement-driven neuroinflammation as first-in-kind treatments for millions of people living with serious neuroinflammatory diseases of the body, brain and eye. Our novel scientific approach focuses on C1q, the initiating molecule of classical complement’s potent inflammatory pathway that when misdirected can lead to tissue damage and loss in a host of diseases. By targeting C1q, our immunotherapies are designed to stop this neuroinflammatory cascade before it starts. Our pipeline spans three diverse therapeutic areas – autoimmunity, neurodegeneration and ophthalmology – and includes targeted investigational drug candidates designed to address the unmet needs of nearly 10 million people worldwide. Annexon’s mission is to deliver game-changing therapies to patients so that they can live their best lives. To learn more visit annexonbio.com.
Investor Contact:
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com
FAQ
What stock options did Annexon (ANNX) grant to its new employee in August 2025?
What is the vesting schedule for Annexon's (ANNX) August 2025 employee stock options?
What is the exercise price of Annexon's (ANNX) August 2025 inducement grant?
When do the Annexon (ANNX) August 2025 employee stock options expire?
